BTIG Initiates Coverage On Stoke Therapeutics with Neutral Rating, Announces $46 Price Target

BTIG initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Neutral rating and a $46 price target.

Benzinga · 11/12/2019 12:49

BTIG initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Neutral rating and a $46 price target.